822
Views
0
CrossRef citations to date
0
Altmetric
Retraction

Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene

Page 1081 | Published online: 20 Apr 2012

The editor would like to inform the readers that the following article has been withdrawn due to duplication of previously published material:

An author of this article, VC Jordan, noticed that his co-author, SS Ko, included various sections and sentences in this paper that were copied from a number of previously published articles. This has also been confirmed by the editor.

We would like to apologise to the authors of the following papers and to our readers for inadvertently publishing replicated material from these papers, which is not condoned by the publishing and scientific community:

  • Lee WL, Chao HT, Cheng MH, et al. Rational for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. The European Menopause Journal. 2008;60:92-107

  • Vogel V, Constantino J, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer. Cancer Prev Res. 2010;3(6):696-706

  • Vogel. Tipping the Balance for the Primary Prevention of Breast Cancer. JNCI. 2010;102(22):1683-1685

  • Riggs BL and Hartmann LC. Selective Estrogen-Receptor Modulators - Mechanisms of Action and Application to Clinical Practice. NEJM. 2003;348(7):618-629

  • Visvanathan K, Chlebowski R, Hurley P, et al. American Society of Clinical Oncology Clinical Practice Guidline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. J Clin Oncol. 2009;27:3253-3258

  • Gnant M. Can Oral Bisphosphonates Really Reduce the Risk of Breast Cancer in Healthy Women? J Clin Oncol. 2010;3548-3551

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.